anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The safety of this drug during pregnancy has not been established. The use of any drug during pregnancy requires that potential benefits of the drug be weighed against possible hazards to mother and child. Reproduction studies in rats revealed no teratogenic effects from glycopyrrolate; however, the potent anticholinergic action of this agent resulted in diminished rates of conception and of survival at weaning, in a dose-related manner. Other studies in dogs suggest that this may be due to diminished seminal secretion which is evident at high doses of glycopyrrolate. Information on possible adverse effects in the pregnant female is limited to uncontrolled data derived from marketing experience. Such experience has revealed no reports of teratogenic or other fetus-damaging potential. No controlled studies to establish the safety of the drug in pregnancy have been performed.
PROBLEM TO BE SOLVED: To obtain a stable skin lotion capable of forming a uniform film on skin when coated and organoleptically excellent by including a complex comprising a ceramide, a phospholipid and cholesterol and a polyhydric alcohol. SOLUTION: This skin lotion is obtained by including (A) >=0.01 wt.% of a complex comprising a ceramide, a phospholipid and cholesterol and (B) a polyhydric alcohol in an amount of 10-100 times based on the ingredient A. N-Stearoylphytosphingosine, etc., can be used as the ceramide of the ingredient A and the content of the ceramide in the complex is preferably 20-40 wt.%. Sphingomyelin, soybeans, etc., can be used as the phospholipid in the ingredient A. The amount thereof in the complex is preferably 35-70 wt.%. Dipropylene glycol, etc., are cited as the ingredient B and the amount thereof formulated in the skin preparation for external use is preferably 1-40 wt.%. An ointment, a cream, a lotion, etc., are cited as the form of use of the skin preparation for external use.
Chronic Obstructive Pulmonary Disease (COPD) is the forth leading cause of mortality worldwide. COPD often impairs balance due to decreased physical activity, muscle weakness, and compromised respiratory function. Virtual Reality training addresses these issues by offering an immersive and engaging environment that enhances patient motivation and adherence to rehabilitation. The technology allows for personalized and controlled balance exercises, progressively increasing the difficulty to match the patient's skill level and providing real-time feedback. By integrating cognitive and motor tasks, VR promotes a comprehensive approach to balance training, improving sensory integration and postural control.

Research indicates that VR training can enhance both static and dynamic balance, helping patients maintain stability in various conditions. It improves the integration of sensory inputs crucial for balance, while also contributing to muscle strength and endurance. This results in a reduction in fall frequency, as patients become more adept at managing balance and are less likely to fall during daily activities. Additionally, VR training teaches specific fall prevention strategies and boosts patient confidence, which further mitigates the fear of falling-a common issue among COPD patients.

Incorporating VR training into physical therapy programs for COPD patients can be highly beneficial. Its ability to provide engaging and customizable exercises makes it a valuable tool in addressing balance issues and reducing fall risks. However, it is essential to ensure that VR training is conducted under proper supervision to avoid potential accidents, especially in patients with severe COPD or additional health concerns. Overall, VR training represents a significant advancement in rehabilitation, offering a novel and effective approach to managing balance and fall risks in COPD patients. The purpose of study is to determine whether VR training has significant effects on balance and fall risk of patients with COPD (GOLD standard stage I \& II).
A pharmaceutical composition and method for treating opioid overdose, opioid dependency, and xylazine exposure is disclosed, utilizing an aqueous solution of sodium chloride. This solution contains active ingredients such as naloxone and yohimbine in specific concentrations, with naloxone targeting opioid overdose and yohimbine aimed at counteracting Xylazine effects. In various embodiments, additional components like tolazoline and different buffers can be included. The disclosure introduces a unique delivery system that features a capsule with a vibrating mesh atomizer for efficient administration. Specifically, for yohimbine, a dual-reservoir capsule design facilitates controlled mixing with diluents or buffers. The administration of this pharmaceutical composition can be achieved through multiple methods, including intramuscular, intravenous, and atomized routes. The atomizing device incorporates a removable cap and a resilient air bladder, ensuring effective drug delivery. This system offers precision and adaptability in treating conditions related to opioid overdose, dependency, and Xylazine exposure.
The placebo was calcium citrate with a daily dose of 65 mg/kg. The daily dose of each substance was divided into three doses given at mealtime.
Lifestyle factors-such as diet, physical activity (PA), smoking, and alcohol consumption-have a significant impact on mortality as well as healthcare costs. Moreover, they play a crucial role in the development of type 2 diabetes mellitus (DM2). There also seems to be a link between lifestyle behaviours and insulin resistance, which is often a precursor of DM2. This study uses an enhanced Healthy Living Index (HLI) integrating accelerometric data and an Ecological Momentary Assessment (EMA) to explore differences in lifestyle between insulin-sensitive (IS) and insulin-resistant (IR) individuals. Moreover, it explores the association between lifestyle behaviours and inflammation. Analysing data from 99 participants of the mPRIME study (57 women and 42 men; mean age 49.8 years), we calculated HLI scores-ranging from 0 to 4- based on adherence to specific low-risk lifestyle behaviours, including non-smoking, adhering to a healthy diet, maximally moderate alcohol consumption, and meeting World Health Organization (WHO) PA guidelines. Insulin sensitivity was assessed using a Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and C-reactive protein (CRP) levels were used as a proxy for inflammation. Lifestyle behaviours, represented by HLI scores, were significantly different between IS and IR individuals (U = 1529.0; p = 0.023). The difference in the HLI score between IR and IS individuals was mainly driven by lower adherence to PA recommendations in the IR group. Moreover, reduced PA was linked to increased CRP levels in the IR group (r = -0.368, p = 0.014). Our findings suggest that enhancing PA, especially among individuals with impaired insulin resistance, holds significant promise as a preventive strategy.
The Multilevel Intervention condition will receive tailored and targeted messages about vaccination. Health educators will also deliver motivational interview sessions to patients eligible to receive the vaccines during the first 6 months of the study. To supplement these encounters, health educators will also send patients mail, emails and/or text message-based informational materials (including videos, testimonials, and resources) that reinforce the benfits of vaccines.
The recommended activity for peritoneovenous shunt scintigraphy in adult patients is 37 MBq to 111 MBq (1 mCi to 3 mCi) by intraperitoneal injection and the number of particles per single injection should be 200,000 to 700,000 with the recommended number of approximately 350,000. Depending on the activity added and volume of the final radiolabeled product, the volume of the dose may vary from 0.2 mL to 1.9 mL. For calculation of the number of particles to be administered, see Recommended Dosage for Lung Perfusion Scintigraphy in Adult Patients [see Dosage and Administration (2.3)]. Assure uniform mixing with peritoneal fluid. 

Alternatively, administer the drug by percutaneous transtubal injection. The recommended activity for percutaneous transtubal administration in adult patients is 12 MBq to 37 MBq (0.3 mCi to 1 mCi) in a volume not to exceed 0.5 mL.
All enrolled participants were randomized to receive Carvedilol or Placebo in a 2-way crossover design. Each intervention was administered over 8 weeks before switching to the alternative intervention. The study was terminated early, and data were not unblinded so participants cannot be reported separately.
Somatic or acquired mutations are postzygotic genetic variations that can occur within any tissue. These mutations accumulate during aging and have classically been linked to malignant processes. Tremendous advancements over the past years have led to a deeper understanding of the role of somatic mutations in benign and malignant age-related diseases. Here, we review the somatic mutations that accumulate in the blood and their connection to disease states, with a particular focus on inflammatory diseases and myelodysplastic syndrome. We include a definition of clonal hematopoiesis (CH) and an overview of the origins and implications of these mutations. In addition, we emphasize somatic disorders with overlapping inflammation and hematologic disease beyond CH, including paroxysmal nocturnal hemoglobinuria and aplastic anemia, focusing on VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome. Finally, we provide a practical view of the implications of somatic mutations in clinical hematology, pathology, and beyond.
Disclosed is a hair styling composition which includes a vinyl copolymer and a nonaqueous solvent. Another disclosed hair styling composition contains a vinyl copolymer, a nonaqueous solvent, a urethane copolymer, a polyester and optionally a second nonaqueous solvent. Film formers and other additives may be included in the composition. The compositions are applied to the hair. Heat may be used in connection with the application. A method of making the compositions by adding copolymers one at a time and stirring until clear mixtures are obtained after each addition is disclosed.
BACKGROUND: Psychoactive drugs frequently cause delirium adverse events in older adults. However, few data on the relationship between antidepressants and delirium are available. Here, we investigated the association between antidepressant prescription and pharmacovigilance reports of delirium in older adults.
METHODS: Using the World Health Organization's VigiBase® global pharmacovigilance database from 1967 to 2022, we performed a disproportionality analysis in order to probe the putative associations between each antidepressant class (non-selective monoamine reuptake inhibitors (NSMRIs), selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), alpha-2-adrenergic receptor antagonists, and other antidepressants) and reports of delirium in people aged 65 or over. We calculated the reporting odds ratios (r-OR) and their 95% confidence interval ([95%CI]) with logistic regression models before and after adjustment for confounding factors. Secondary analyses were performed for each drug and within each class by age group (65-74, and 75 and over). We also studied the reports of concomitant delirium and hyponatremia.
RESULTS: Our main analysis included 87,524 cases of delirium. After adjustment for confounders, a significant association was found between delirium and all antidepressant classes other than SNRIs. Intraclass disparities were found for the association between the most frequently prescribed antidepressants and reports of delirium. An elevated risk of reports of concomitant delirium and hyponatremia was found for SSRIs (4.46 [4.01-4.96]), SNRIs (1.25 [1.07-1.46]), MAOIs (1.72 [1.41-2.09]), and the "other antidepressants" class (1.47 [1.30-1.65]).
CONCLUSIONS: There was a significant association between reports of delirium and antidepressant classes (other than SNRIs). However, this association varied from one drug to another within a given antidepressant class. Moreover, this association could not always be explained by antidepressant-induced hyponatremia.
FIELD: cosmetics. SUBSTANCE: plant raw: Altai sea back-thorn and ginseng dry biomass at ratio 1:1. Extraction of raw is carried out with 50% aqueous-spirituous liquid twice. Firstly, raw and alcohol solution are taken at ratio 1:7, and then at ratio 1:3. Residue obtained after first extraction is repeated after decantation and filtration, and the end product is obtained by mixing of both extracts. At the both cases extraction process is carried out at the room temperature for 45-50 h. EFFECT: enhanced biological activity of the end product.
Equine veterinarians frequently treat patients in non-climate-controlled (i.e., hospitalized) settings. In colder environments, intravenous (IV) fluid administration can contribute to patient hypothermia. The objective of this study was to evaluate three IV fluid warming mechanisms to determine their effect on fluid outflow temperatures at ambient temperatures of 21-22°C and 3.5°C. In this study, fluid outflow temperatures were measured using three warming mechanisms: (1) pre-warmed fluids at 42°C, (2) an in-line warming device placed 163 cm away from the Luer-lock fluid line adaptor (location 1) on the fluid line, and (3) an in-line warming device placed 88 cm away from the Luer-lock fluid line adaptor (location 2) on the fluid line. These warming mechanisms were compared to outflow temperatures measured using no warming mechanism at ambient temperatures of 21-22°C and 3.5°C with flow rates of ∼12 L/hour (gravity flow bolus) and 999 mL/hour. All outflow temperatures were measured with a thermistor. At ∼12L/hour, the use of pre-warmed fluids increased outflow temperatures at both ambient temperatures of 21-22°C and 3.5°C ambient temperatures and an in-line warming device placed at location 1 significantly increased outflow temperatures in 3.5°C ambient temperatures. At 999 mL/hour, use of pre-warmed fluids or an in-line warming device, placed at either location, increased outflow temperatures at ambient temperatures of 21°C or 3.5°C.
Although neuroanatomical and physiological understanding of the cerebellum has evolved over recent decades and continues to develop, there is much that remains to be expounded upon, especially with regard to nonmotor roles. Neurocognitive and language processing is one area where involvement of the cerebellum is no longer in question, but the extent and mechanism of this relationship have yet to be defined. For example, which of the cerebellar hemispheres is involved continues to be debated. We present a case wherein a thrombus in the basilar artery led to bihemispheric cerebellar strokes with profound mixed effects on the patient's language and cognition. To the authors' knowledge, this is the first reported case of bilateral cerebellar strokes resulting in a mixed aphasia reported in scientific literature. This demonstrates the importance of continued research into a model for cerebellar function and the clinical impact of lesions to various cerebellar regions.
Patients receive everolimus PO QD on days -14 and then 1-28. Patients also receive cetuximab IV over 60-120 minutes on days -7 and then once weekly beginning on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
The amber oral dose syringe should be used to withdraw the prescribed amount of Rapamune Oral Solution from the bottle. Empty the correct amount of Rapamune from the syringe into only a glass or plastic container holding at least two (2) ounces (1/4 cup, 60 mL) of water or orange juice. No other liquids, including grapefruit juice, should be used for dilution [see Drug Interactions (7.3), Clinical Pharmacology (12.3)]. Stir vigorously and drink at once. Refill the container with an additional volume [minimum of four (4) ounces (1/2 cup, 120 mL)] of water or orange juice, stir vigorously, and drink at once.

Rapamune Oral Solution contains polysorbate 80, which is known to increase the rate of di-(2-ethylhexyl)phthalate (DEHP) extraction from polyvinyl chloride (PVC). This should be considered during the preparation and administration of Rapamune Oral Solution. It is important that these recommendations be followed closely.
Background and Objectives: Scrotal swelling or hydrocele is a rare complication of acute pancreatitis described in the literature. We present a case of penoscrotal swelling caused by the first attack of acute interstitial edematous alcohol-induced pancreatitis in a young male patient. Case report: A 22-year-old man was admitted to the emergency unit due to diarrhea and vomiting since morning which was followed by severe abdominal pain. Urgent abdominal multislice CT scan showed steatosis, pancreatic swelling and acute peripancreatic fluid collection (interstitial edematous pancreatitis). Also, scan showed fluid between small bowel loops and along the anterior renal fascia, while there was minimal amount of fluid in the Douglas space. There was no sign of penoscrotal swelling. On the second day of admission, the patient developed left scrotal swelling and mild pain without erythema. On the fourth day, a control CT scan showed progression to moderately severe pancreatitis (CT severity index 4). Dilated scrotal veins of the pampiniform venous plexus with an increased caliber of the testicular veins were present on both sides, from the scrotum to the level of the inguinal canal. Penoscrotal swelling was significantly reduced on discharge. Conclusions: Penoscrotal swelling is a rare complication or manifestation of acute inflammation of the pancreas. It is important to identify scrotal swelling caused by pancreatitis because in severe cases it can be related to possible infertility in the future.
BACKGROUND: Brain iron overload may induce neuronal death and lead to cognitive impairment. The hippocampus is a critical limbic structure involved in memory. This study aimed to investigate iron overload and its role in hippocampal damage and memory impairment using a rat model.
METHODS: Young rats (2 weeks old) received intraperitoneal injections of high-dose iron solution (Group H, n = 10), low-dose iron solution (Group L, n = 10) and normal saline as control (Group D, n = 5). The Morris water maze (MWM) test was performed on all rats to evaluate their spatial reference memory by assessing their escape latency time and number of platform crossing. The iron content and neuronal damage in hippocampal tissue sections of the rats were assessed semi-quantitatively using diaminobenzidine (DAB)-enhanced Perl's Prussian blue (PPB) staining, and their correlation with spatial reference memory performance was evaluated.
RESULTS: The escape latency in Group H was significantly longer compared to Groups L and D (P < 0.05). The number of platform crossings was significantly lower in Group H than in Group L or D (P < 0.001). The neuronal cells in Group H had more brown iron deposits than those of Groups L and D. There were significant correlations between the severity of structural damage in the hippocampal tissue and the number of platform crossings (P1 = 0.001 for Group H; P2 = 0.043 for Group L).
CONCLUSION: This study showed an association between hippocampal iron-induced structural damage and spatial reference memory impairment in a rat model. This work should advance our understanding of hippocampal iron overload on cognitive functioning.
In accordance with the present invention, there have been identified extracts from a tropical plant that initiate paclitaxel-like microtubule bundling. Bioassay-directed purification yields the steroid taccalonolide A. Taccalonolide, like paclitaxel, intitiates the formation of abnormal interphaes and mitotic microtubules. Cells treated with taccalonolide exhibit thick bundles of microtubules that appear to nucleate independent of the microtubule organizing center. Abnormal mitotic spindles consisting of multi-polar spindles are initiated by taccalonolide and resemble abnormal mitotic spindles found in the presence of paclitaxel. Like paclitaxel, taccalonolide causes the breakdown of the nucleus into micronuclei. Taccalonolide causes G2/M arrest, Bc1-2 phosphorylation and initiates an apoptotic cascade that includes the activation of caspase 3. Taccalonolide is an effective inhibitor of proliferation agaisnt both SK-OV-3 and MDA-MB-435 cells with IC50 values of 2.3νM and 2.1νM respectively. In contrast to paclitaxel, taccalonolide is effective against the multidrug resistant SKVLB-1 cellline and thus appears to be a poor substrate for P-glycoprotein-mediated transport. Although taccalonolide is almost equipotent with paclitaxel in its effects on cellular microtubules, it is much less potent than paclitaxel in its ability to initiate the polymerization of purified tubulin and microtubule protein. Taccalonolide A is the first microtobule stabilizing agent to be discovered from a plant since identification of the mechanism of action of paclitaxel and it is the first natural product steroid identified to have these cellular effects.
Patient will be phone screened and/or have a physical and neurological examination to determine if it is appropriate for them to participate in this study. This testing includes the Unified Parkinson's Disease Rating Scale, Part III (UPDRS III). Research assistants will explain the study and obtain informed consent. There will be three consecutive days of testing, as well as 2 follow up visits at 1 and 4 weeks. Visits include the following: Patients will have sensors put on their hands, feet, and chest. These sensors measure their movement while they perform kinematic tasks such as forward walking, wrist movements, and the UPDRS III. Patients will also be given vibrotactile stimulation for a total of 4 hours throughout the day. During this time, patients will be provided with books/movies as entertainment, and they may move around freely. Patients will also be asked to complete several questionnaires throughout the visits about their Parkinson's symptoms.
The objective of the present invention is to provide a method of synthesizing a product more rapidly and with a higher yield than the conventional method, via a hydrothermal reaction and/or a high-temperature synthesis reaction using microwaves, using carbon nanoparticles surface-coated with PEG or PEI. According to the present invention, in the case of the synthesis method using microwaves, surprisingly, a purpose of genes delivered into synthesized particles was determined differently according to a change in the molecular weight of PEI used in the reaction. In the case of the PEI-coated carbon nanoparticles, bonding with fluorescent dyes of various kinds was possible through surface modifications, and thus the composition comprising the same was shown to be applicable to a multi-imaging system. Further, in the case of PEG-coated carbon nanoparticles, pharmaceutically effective components and genes of different kinds, and the like can be loaded through applications of aromatic structures inside the particles, and thus the composition comprising the same was appropriate as a formulation for the treatment of chemical therapy for tumor and/or diseased cells; and when irradiated with near-infrared rays, its exothermic capacity due to photosensitivity had shown the ability to kill specifically tumor and/or diseased cells in the proximity to the particles. Accordingly, the compositions of the present invention have shown superiority with respect to combination therapies (chemotherapy and/or photosensitive pyrotherapy) based on the carbon nanoparticles surface-coated with PEG or PEI proposed in the present invention, and according to an intended purpose of use, target ligands may be attached through surface modification of the particles. Thus, the compositions may be further utilized in a target therapy which selectively targets a target cell or tissue. Furthermore, delivery efficiency of genes into cells and/or tissues due to high bioavailability of the particles may be utilized in the fields such as fundamental research, cosmetics, and medicine.